Superluminal Medicines
MA - BostonBiotechnology
Focus: Superluminal Medicines is an AI-driven GPCR-targeting small molecule biotech focused on neurology and metabolic diseases, recently raised $60M Series B to advance obesity therapy into clinical development.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Open Jobs
6
Should You Work at Superluminal Medicines?
AI assessmentStrong fit for discovery/translational researchers and early-stage clinical developers seeking equity upside and technical depth; higher risk for those prioritizing revenue stability or clear clinical proof-of-concept.
Why Work Here
- Recently closed $60M Series B (September 2026) with strong institutional backing (BVF Partners), providing 2-3 years of clinical runway and hiring momentum
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SUN-0864 or placebo
Healthy ParticipantsClinical Trials (1)
NCT07905560A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Phase 1Help build intelligence for Superluminal Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.